African descent and glaucoma evaluation study (ADAGES) III. Ancestry differences in visual function in healthy eyes

Archives of Ophthalmology

Volumn 128, Issue 5, 2010, Pages 551-559

  Racette, Lyne ^a   Liebmann, Jeffrey M ^b   Girkin, Christopher A ^c   Zangwill, Linda M ^a   Jain, Sonia ^a   Becerra, Lida M ^a   Medeiros, Felipe A ^a   Bowd, Christopher ^a   Weinreb, Robert N ^a   Boden, Catherine ^a   Sample, Pamela A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICA; ARTICLE; CLINICAL TRIAL; EUROPE; EVALUATION; FEMALE; GLAUCOMA; HUMAN; HUMAN EXPERIMENT; INTRAOCULAR PRESSURE; MALE; NORMAL HUMAN; OPTIC DISK; PERIMETRY; PRIORITY JOURNAL; RELIABILITY; VISION;

ADULT; AFRICAN AMERICANS; AGED; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMOSCOPY; OPTIC NERVE DISEASES; PERIMETRY; PROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VISION DISORDERS; VISUAL ACUITY; VISUAL FIELDS;

EID: 77952115082     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.58     Document Type: Article

References (51)

1. Thylefors B, Negrel AD, Pararajasegaram R. Epidemiologic aspects of global blindness prevention. Curr Opin Ophthalmol. 1992;3(6):824-834.
2. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363(9422):1711-1720.
3. Friedman DS, Wolfs RC, O'Colmain BJ, et al; Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122(4):532-538.
4. Friedman DS, Jampel HD, Munoz B, West SK. The prevalence of open-angle glaucoma among blacks and whites 73 years and older: the Salisbury Eye Evaluation Glaucoma Study. Arch Ophthalmol. 2006;124(11):1625-1630.
5. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 1991;325(20):1412-1417.
6. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore Eye Survey. JAMA. 1991;266(3):369-374.
7. Wilensky JT, Gandhi N, Pan T. Racial influences in open-angle glaucoma. Ann Ophthalmol. 1978;10(10):1398-1402.
8. Martin MJ, Sommer A, Gold EB, Diamond EL. Race and primary open-angle glaucoma. Am J Ophthalmol. 1985;99(4):383-387.
9. Leske MC, Wu SY, Honkanen R, et al; Barbados Eye Studies Group. Nine-year incidence of open-angle glaucoma in the Barbados Eye Studies. Ophthalmology. 2007;114(6):1058-1064.
10. Leske MC, Wu SY, Hyman L, Nemesure B, Hennis A, Schachat AP; Barbados Eye Studies Group. Four-year incidence of visual impairment: Barbados Incidence Study of Eye Diseases. Ophthalmology. 2004;111(1):118-124.
11. Cedrone C, Mancino R, Cerulli A, Cesareo M, Nucci C. Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects. Prog Brain Res. 2008;173:3-14.
12. Racette L, Wilson MR, Zangwill LM, Weinreb RN, Sample PA. Primary open-angle glaucoma in blacks: a review. Surv Ophthalmol. 2003;48(3):295-313.
13. Girkin CA. Primary open-angle glaucoma in African Americans. Int Ophthalmol Clin. 2004;44(2):43-60.
14. Kosoko-Lasaki O, Olivier MM. African American health disparities: glaucoma as a case study. Int Ophthalmol Clin. 2003;43(4):123-131.
15. Muñoz B, West SK, Rubin GS, et al. Causes of blindness and visual impairment in a population of older Americans: the Salisbury Eye Evaluation Study. Arch Ophthalmol. 2000;118(6):819-825.
16. Grant WM, Burke JF Jr. Why do some people go blind from glaucoma? Ophthalmology. 1982;89(9):991-998.
17. Hiller R, Kahn HA. Blindness from glaucoma. Am J Ophthalmol. 1975;80(1):62-69.
18. Wilson R, Richardson TM, Hertzmark E, Grant WM. Race as a risk factor for progressive glaucomatous damage. Ann Ophthalmol. 1985;17(10):653-659. (Pubitemid 16191675)
19. Wilson MR, Kosoko O, Cowan CL Jr, et al. Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St Lucia, West Indies. Am J Ophthalmol. 2002;134(3):399-405.
20. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT), V: subgroup differences at enrollment. Ophthalmic Surg. 1993;24(4):232-240.
21. Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999;106(4):653-662.
22. Quigley HA, Tielsch JM, Katz J, Sommer A. Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage. Am J Ophthalmol. 1996;122(3):355-363. (Pubitemid 26300052)
23. Smith SD, Katz J, Quigley HA. Analysis of progressive change in automated visual fields in glaucoma. Invest Ophthalmol Vis Sci. 1996;37(7):1419-1428. (Pubitemid 26177317)
24. Lichter PR, Musch DC, Gillespie BW, et al; CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943-1953.
25. Katz J, Gilbert D, Quigley HA, Sommer A. Estimating progression of visual field loss in glaucoma. Ophthalmology. 1997;104(6):1017-1025. (Pubitemid 27255415)
26. Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol. 1999;117(5):573-583.
27. Racette L, Boden C, Kleinhandler SL, et al. Differences in visual function and optic nerve structure between healthy eyes of blacks and whites. Arch Ophthalmol. 2005;123(11):1547-1553.
28. Sample PA, Girkin CA, Zangwill LM, et al; African Descent and Glaucoma Evaluation Study Group. The African Descent and Glaucoma Evaluation Study (ADAGES): design and baseline data. Arch Ophthalmol. 2009;127(9):1136-1145.
29. Keltner JL, Johnson CA, Levine RA, et al. Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2005;123(9):1201-1206.
30. Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO; Ocular Hypertension Treatment Study Group. Confirmation of visual field abnormalities inthe Ocular Hypertension Treatment Study. Arch Ophthalmol. 2000;118(9):1187- 1194.
31. Tafreshi A, Sample PA, Liebmann JM, et al. Visual function specific perimetry to identify glaucomatous visual loss using three different definitions of visual field abnormality. Invest Ophthalmol Vis Sci. 2009;50(3):1234-1240.
32. Keltner JL, Johnson CA, Cello KE, et al; Ocular Hypertension Treatment Study Group. Visual field quality control in the Ocular Hypertension Treatment Study (OHTS). J Glaucoma. 2007;16(8):665-669.
33. Bengtsson B, Olsson J, Heijl A, Rootzen H. A new generation of algorithms for computerized threshold perimetry, SITA. Acta Ophthalmol Scand. 1997;75(4):368-375. (Pubitemid 27470462)
34. Racette L, Sample PA. Short-wavelength automated perimetry. Ophthalmol Clin North Am. 2003;16(2):227-236, vi-vii.
35. Dacey DM, Lee BB. The "blue-on" opponent pathway in primate retina originates from a distinct bistratified ganglion cell type. Nature. 1994;367(6465):731-735.
36. Sample PA, Johnson CA, Haegerstrom-Portnoy G, Adams AJ. Optimum parameters for short-wavelength automated perimetry. J Glaucoma. 1996;5(6):375-383. (Pubitemid 26418303)
37. Bengtsson B. A new rapid threshold algorithm for short-wavelength automated perimetry. Invest Ophthalmol Vis Sci. 2003;44(3):1388-1394. (Pubitemid 36297863)
38. Kelly DH. Frequency doubling in visual responses. J Opt Soc Am. 1966;56:1628-1633.
39. Johnson CA, Samuels SJ. Screening for glaucomatous visual field loss with frequency-doubling perimetry. Invest Ophthalmol Vis Sci. 1997;38(2):413-425. (Pubitemid 27085699)
40. Maddess T. Performance of nonlinear visual units in ocular hypertension and glaucoma. Clin Vis Sci. 1992;7(5):371-383.
41. Anderson AJ, Johnson CA. Mechanisms isolated by frequency-doubling technology perimetry. Invest Ophthalmol Vis Sci. 2002;43(2):398-401.
42. White AJ, Sun H, Swanson WH, Lee BB. An examination of physiological mechanisms underlying the frequency-doubling illusion. Invest Ophthalmol Vis Sci. 2002;43(11):3590-3599. (Pubitemid 35334369)
43. Turpin A, McKendrick AM, Johnson CA, Vingrys AJ. Performance of efficient test procedures for frequency-doubling technology perimetry in normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 2002;43(3):709-715. (Pubitemid 34184488)
44. Racette L, Medeiros FA, Zangwill LM, Ng D, Weinreb RN, Sample PA. Diagnostic accuracy of the Matrix 24-2 and original N-30 frequency-doubling technology tests compared with standard automated perimetry. Invest Ophthalmol Vis Sci. 2008;49(3):954-960.
45. Liang KY, Zeger SL. Longitudinal data-analysis using generalized linear-models. Biometrika. 1986;73(1):13-22.
46. Rubin GS, West SK, Muñoz B, et al; SEE Project Tea. A comprehensive assessment of visual impairment in a population of older Americans: the SEE Study. Invest Ophthalmol Vis Sci. 1997;38(3):557-568. (Pubitemid 27143125)
47. Ng M, Racette L, Pascual JP, et al. Comparing the full threshold and Swedish interactive thresholding algorithms for short-wavelength automated perimetry. Invest Ophthalmol Vis Sci. 2009;50(4):1726-1733.
48. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713, 829-830.
49. Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I; European Glaucoma Prevention Study (EGPS) Group. Results of the European Glaucoma Prevention Study. Ophthalmology. 2005;112(3):366-375.
50. Kosoko-Lasaki O, Gong G, Haynatzki G, Wilson MR. Race, ethnicity and prevalence of primary open-angle glaucoma. J Natl Med Assoc. 2006;98(10):1626-1629. (Pubitemid 44682957)
51. Rosenberg NA, Pritchard JK, Weber JL, et al. Genetic structure of human populations. Science. 2002;298(5602):2381-2385.